All In Biotech

Drug Trial Radar · NCT06368804

Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis

Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With Pseudomonas Aeruginosa in Adults With Bronchiectasis: a Non-inferiority Randomized Controlled Trial.

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

196

Planned (sponsor's estimate)

Start

Sep 15, 2024

Primary completion

Mar 15, 2025

Study completion Sep 15, 2028

Sponsor

Lead sponsor
Centre Hospitalier Intercommunal CreteilAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Assistance Publique - Hôpitaux de Paris
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic airways infection with Pseudomonas aeruginosa (PA) is associated with increased frequency of exacerbations, deterioration in quality of life and increased mortality in adult patients with bronchiectasis. Current guidelines suggest the prescription of an eradication antibiotic treatment for a first episode of PA infection (early PA infection). Several antibiotic regimens may be proposed, ranging from a monotherapy with oral fluoroquinolone (FQ) to an intravenous cotherapy with the addition of inhaled antibiotics that seems to improve the rate of PA eradication. As no study strictly favoured one regimen, current practices are heterogeneous and could certainly benefit from stronger evidence, with both medical and economic impact.

Conditions

  • Bronchiectasis

Interventions

  • Antibiotic monotherapy treatment and follow-upDrug

    1. a 3-months treatment period, including: * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d) * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ; 2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).

  • Antibiotic bitherapy treatment and follow-upDrug

    1. a 3-months treatment period, including: * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d) * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ; 2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PA-eradication rateTime frame: 6 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Amiens-Picardie

    Amiens, France · Recruiting

  • CHU Haut Leveque, Bordeaux

    Bordeaux, France · Recruiting

  • CHRU Brest

    Brest, France · Recruiting

  • CH Pontoise

    Cergy-Pontoise, France · Recruiting

  • Centre hospitalier intercommunal de Créteil

    Créteil, France · Recruiting

  • APHP, Henri Mondor

    Créteil, France · Recruiting

  • Hôpital de la Croix Rousse, HCL, Lyon

    Lyon, France · Not yet recruiting

  • Clinique St Joseph

    Marseille, France · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • CHU H. Pasteur, Nice

    Nice, France · Not yet recruiting

  • Hôpital Pitié Salpêtrière

    Paris, France · Recruiting

  • APHP, Cochin

    Paris, France · Recruiting

  • APHP, Saint Louis

    Paris, France · Recruiting

  • APHP, Tenon

    Paris, France · Recruiting

  • Hôpital Foch, Suresnes

    Suresnes, France · Recruiting

  • CHU H. Larrey, Toulouse

    Toulouse, France · Recruiting

  • CH Versailles

    Versailles, France · Recruiting

  • CH Villefranche s/Saône

    Villefranche-sur-Saône, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.